Standardized methods to quantify thrombogenicity of blood-contacting materials via thromboelastography

Venkat Shankarraman, Grace Davis-Gorman, Jack G. Copeland, Michael Caplan, Paul F. McDonagh

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Blood coagulation is the most significant complication of vascular biomaterials. A straightforward, sensitive, and standard measure of the compatibility of these materials with whole blood (hemocompatibility) is necessary to avoid coagulation. Current techniques used quantify only individual clotting components and are poor predictors of coagulation. The thromboelastograph (TEG) provides a measure of overall clot formation from whole blood. Although TEG is very common in clinical settings, its application to biomaterials is limited partly due to difficulty in sample preparation. In this protocol, whole blood samples are incubated with (1) biomaterials (tube with clamped ends) and (2) endothelial cells cultured on biomaterial surfaces (12-well plate) under controlled shearing conditions (10 rpm on rocker, at 37°C), and then the blood is transferred to the TEG to measure clot formation. TEG clearly discriminates among the R-times (time until initial clot formation) of expanded poly(tetrafluoroethylene), poly(urethane), and Tygon tubing. Marked differences in R-time are also seen when endothelial cells are cultured on various extracellular matrix proteins and proteoglycans. Thus, R-time provides a robust metric of overall thrombogenicity of biomaterials, and these procedures provide a standardized method for TEG to facilitate direct comparison among candidate biomaterials undergoing in-vitro testing.

Original languageEnglish (US)
Pages (from-to)230-238
Number of pages9
JournalJournal of Biomedical Materials Research - Part B Applied Biomaterials
Volume100 B
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Biocompatible Materials
Biomaterials
Blood
Coagulation
Endothelial cells
Extracellular Matrix Proteins
Urethane
Proteoglycans
Tubing
Polytetrafluoroethylenes
Shearing
Proteins
Testing

Keywords

  • biocompatible materials
  • blood coagulation
  • endothelial cells
  • thromboelastogram
  • vascular graft

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biomaterials

Cite this

Standardized methods to quantify thrombogenicity of blood-contacting materials via thromboelastography. / Shankarraman, Venkat; Davis-Gorman, Grace; Copeland, Jack G.; Caplan, Michael; McDonagh, Paul F.

In: Journal of Biomedical Materials Research - Part B Applied Biomaterials, Vol. 100 B, No. 1, 01.2012, p. 230-238.

Research output: Contribution to journalArticle

Shankarraman, Venkat ; Davis-Gorman, Grace ; Copeland, Jack G. ; Caplan, Michael ; McDonagh, Paul F. / Standardized methods to quantify thrombogenicity of blood-contacting materials via thromboelastography. In: Journal of Biomedical Materials Research - Part B Applied Biomaterials. 2012 ; Vol. 100 B, No. 1. pp. 230-238.
@article{55af03f5b5874da6b9453398f51ac7fc,
title = "Standardized methods to quantify thrombogenicity of blood-contacting materials via thromboelastography",
abstract = "Blood coagulation is the most significant complication of vascular biomaterials. A straightforward, sensitive, and standard measure of the compatibility of these materials with whole blood (hemocompatibility) is necessary to avoid coagulation. Current techniques used quantify only individual clotting components and are poor predictors of coagulation. The thromboelastograph (TEG) provides a measure of overall clot formation from whole blood. Although TEG is very common in clinical settings, its application to biomaterials is limited partly due to difficulty in sample preparation. In this protocol, whole blood samples are incubated with (1) biomaterials (tube with clamped ends) and (2) endothelial cells cultured on biomaterial surfaces (12-well plate) under controlled shearing conditions (10 rpm on rocker, at 37°C), and then the blood is transferred to the TEG to measure clot formation. TEG clearly discriminates among the R-times (time until initial clot formation) of expanded poly(tetrafluoroethylene), poly(urethane), and Tygon tubing. Marked differences in R-time are also seen when endothelial cells are cultured on various extracellular matrix proteins and proteoglycans. Thus, R-time provides a robust metric of overall thrombogenicity of biomaterials, and these procedures provide a standardized method for TEG to facilitate direct comparison among candidate biomaterials undergoing in-vitro testing.",
keywords = "biocompatible materials, blood coagulation, endothelial cells, thromboelastogram, vascular graft",
author = "Venkat Shankarraman and Grace Davis-Gorman and Copeland, {Jack G.} and Michael Caplan and McDonagh, {Paul F.}",
year = "2012",
month = "1",
doi = "10.1002/jbm.b.31942",
language = "English (US)",
volume = "100 B",
pages = "230--238",
journal = "Journal of Biomedical Materials Research - Part B Applied Biomaterials",
issn = "0021-9304",
publisher = "Heterocorporation",
number = "1",

}

TY - JOUR

T1 - Standardized methods to quantify thrombogenicity of blood-contacting materials via thromboelastography

AU - Shankarraman, Venkat

AU - Davis-Gorman, Grace

AU - Copeland, Jack G.

AU - Caplan, Michael

AU - McDonagh, Paul F.

PY - 2012/1

Y1 - 2012/1

N2 - Blood coagulation is the most significant complication of vascular biomaterials. A straightforward, sensitive, and standard measure of the compatibility of these materials with whole blood (hemocompatibility) is necessary to avoid coagulation. Current techniques used quantify only individual clotting components and are poor predictors of coagulation. The thromboelastograph (TEG) provides a measure of overall clot formation from whole blood. Although TEG is very common in clinical settings, its application to biomaterials is limited partly due to difficulty in sample preparation. In this protocol, whole blood samples are incubated with (1) biomaterials (tube with clamped ends) and (2) endothelial cells cultured on biomaterial surfaces (12-well plate) under controlled shearing conditions (10 rpm on rocker, at 37°C), and then the blood is transferred to the TEG to measure clot formation. TEG clearly discriminates among the R-times (time until initial clot formation) of expanded poly(tetrafluoroethylene), poly(urethane), and Tygon tubing. Marked differences in R-time are also seen when endothelial cells are cultured on various extracellular matrix proteins and proteoglycans. Thus, R-time provides a robust metric of overall thrombogenicity of biomaterials, and these procedures provide a standardized method for TEG to facilitate direct comparison among candidate biomaterials undergoing in-vitro testing.

AB - Blood coagulation is the most significant complication of vascular biomaterials. A straightforward, sensitive, and standard measure of the compatibility of these materials with whole blood (hemocompatibility) is necessary to avoid coagulation. Current techniques used quantify only individual clotting components and are poor predictors of coagulation. The thromboelastograph (TEG) provides a measure of overall clot formation from whole blood. Although TEG is very common in clinical settings, its application to biomaterials is limited partly due to difficulty in sample preparation. In this protocol, whole blood samples are incubated with (1) biomaterials (tube with clamped ends) and (2) endothelial cells cultured on biomaterial surfaces (12-well plate) under controlled shearing conditions (10 rpm on rocker, at 37°C), and then the blood is transferred to the TEG to measure clot formation. TEG clearly discriminates among the R-times (time until initial clot formation) of expanded poly(tetrafluoroethylene), poly(urethane), and Tygon tubing. Marked differences in R-time are also seen when endothelial cells are cultured on various extracellular matrix proteins and proteoglycans. Thus, R-time provides a robust metric of overall thrombogenicity of biomaterials, and these procedures provide a standardized method for TEG to facilitate direct comparison among candidate biomaterials undergoing in-vitro testing.

KW - biocompatible materials

KW - blood coagulation

KW - endothelial cells

KW - thromboelastogram

KW - vascular graft

UR - http://www.scopus.com/inward/record.url?scp=82955203711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955203711&partnerID=8YFLogxK

U2 - 10.1002/jbm.b.31942

DO - 10.1002/jbm.b.31942

M3 - Article

C2 - 22102528

AN - SCOPUS:82955203711

VL - 100 B

SP - 230

EP - 238

JO - Journal of Biomedical Materials Research - Part B Applied Biomaterials

JF - Journal of Biomedical Materials Research - Part B Applied Biomaterials

SN - 0021-9304

IS - 1

ER -